• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Kinoxis Therapeutics

Monday, June 03, 2024
CP
CNS/Neurological
Kinoxis Therapeutics is a private, Australian-based, clinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders. Kinoxis’ development candidates are novel, small molecules that were discovered through a comprehensive medicinal chemistry and screening program at the University of Sydney. Kinoxis' lead compound KNX100 is commencing Phase 2 studies in 2024, with the first study aimed at the treatment of agitation and aggression in dementia patients, and the second study for the treatment of withdrawal symptoms in patients with opioid use disorder. The company also has an early-stage license and development collaboration in place with Boehringer Ingelheim, focused on developing novel compounds targeting the brain oxytocin system.
Kinoxis Therapeutics
Company Website: http://www.kinoxistherapeutics.com/
Lead Product in Development: KNX100 - in development for the treatment of agitation in dementia patients and opioid use disorder.
Number Of Unlicensed Products (For Which You Are Seeking Partners): 1

Company HQ City

Camberwell

Company HQ State

Victoria

Company HQ Country

Australia

CEO/Top Company Official

Hugh Alsop

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS